These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6380880)

  • 1. Altered pressor responses in long-term nitrendipine treatment.
    Simon G; Snyder DK
    Clin Pharmacol Ther; 1984 Sep; 36(3):315-9. PubMed ID: 6380880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acute mild hypercalcemia or of the calcium antagonist nifedipine on cardiovascular responsiveness to norepinephrine or angiotensin II in normal humans.
    Beretta-Piccoli C; Bianchetti MG; Weidmann P; Boehringer K; Link L; Morton JJ
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S306-12. PubMed ID: 6184559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium channel blockade with nitrendipine. Effects on sodium homeostasis, the renin-angiotensin system, and the sympathetic nervous system in humans.
    Luft FC; Aronoff GR; Sloan RS; Fineberg NS; Weinberger MH
    Hypertension; 1985; 7(3 Pt 1):438-42. PubMed ID: 3158605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The calcium channel blocker nitrendipine in single- and multiple-agent antihypertensive regimens: preliminary report of a multicenter study.
    Weber MA; Drayer JI
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1077-84. PubMed ID: 6085371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium and blood pressure regulation in normal and hypertensive subjects.
    Bianchetti MG; Beretta-Piccoli C; Weidmann P; Link L; Boehringer K; Ferrier C; Morton JJ
    Hypertension; 1983; 5(4 Pt 2):II57-65. PubMed ID: 6345376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertensive dysregulation and its modification by calcium channel blockade in nonoliguric renal failure.
    Weidmann P; Schohn D; Gnädinger MP; Bürgisser E; Ferrier C; Jahn H
    Am J Nephrol; 1989; 9(4):269-78. PubMed ID: 2683789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic and metabolic effects of the calcium channel blocking agent nitrendipine.
    Johnson BF; Romero L; Marwaha R
    Clin Pharmacol Ther; 1986 Apr; 39(4):389-94. PubMed ID: 2937598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-angiotensin system in two genetically normotensive strains of Lyon rats.
    Lantelme P; Lo M; Sassard J
    Am J Hypertens; 2000 Mar; 13(3):283-9. PubMed ID: 10777033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of nitrendipine and hydralazine on plasma catecholamines in essential hypertension.
    Lopez LM; Mehta JL; Baz R; Aguila E
    Clin Pharmacol Ther; 1984 Oct; 36(4):444-50. PubMed ID: 6478732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive therapy with the long-acting calcium antagonist nitrendipine.
    Müller FB; Bolli P; Erne P; Block LH; Kiowski W; Bühler FR
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1073-6. PubMed ID: 6085370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body sodium-blood volume state, aldosterone, and cardiovascular responsiveness after calcium entry blockade with nifedipine.
    Marone C; Luisoli S; Bomio F; Beretta-Piccoli C; Bianchetti MG; Weidmann P
    Kidney Int; 1985 Oct; 28(4):658-65. PubMed ID: 3910913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind randomized cross-over study of the efficacy and tolerability of nifedipine and nitrendipine in the treatment of mild to moderate hypertension.
    Heagerty AM; Swales JD
    Br J Clin Pharmacol; 1989 Apr; 27(4):411-6. PubMed ID: 2655687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potassium and norepinephrine- or angiotensin-mediated pressor control in pre-hypertension.
    Bianchetti MG; Weidmann P; Beretta-Piccoli C; Ferrier C
    Kidney Int; 1987 Apr; 31(4):956-63. PubMed ID: 3586502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II.
    Donati L; Bühler FR; Beretta-Piccoli C; Kusch F; Heinen G
    Clin Pharmacol Ther; 1992 Jul; 52(1):50-9. PubMed ID: 1385565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitrendipine vs. long-acting nifedipine in mild, moderate and severe hypertension.
    Guazzi MD; De Cesare N; Galli C; Tamborini G; Salvioni A
    Angiology; 1986 Jul; 37(7):508-18. PubMed ID: 2942062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular pressor responses in treated and untreated essential hypertension.
    Donnelly R; Elliott HL; Howie CA; Sumner DJ; Reid JL
    J Cardiovasc Pharmacol; 1990 Aug; 16(2):191-6. PubMed ID: 1697373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with long-term nitrendipine treatment in essential hypertension.
    Tourkantonis A; Lasaridis A; Settas L
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1090-5. PubMed ID: 6085373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety comparison of nitrendipine and hydralazine as antihypertensive monotherapy.
    Fagan TC; Sternleib C; Vlachakis N; Deedwania PC; Mehta JL
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1109-13. PubMed ID: 6085377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal effects of nitrendipine monotherapy in essential hypertension.
    Thananopavarn C; Golub MS; Eggena P; Barrett JD; Sambhi MP
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1032-6. PubMed ID: 6085362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a calcium entry blocker on blood pressure and renal function during angiotensin-induced hypertension.
    Huelsemann JL; Sterzel RB; McKenzie DE; Wilcox CS
    Hypertension; 1985; 7(3 Pt 1):374-9. PubMed ID: 3158602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.